The registrational Phase 3 study in obese and overweight patients in China
Latest Information Update: 27 Dec 2024
Price :
$35 *
At a glance
- Drugs VCT 220 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- 27 Dec 2024 New trial record
- 23 Dec 2024 According to a Corxel Pharmaceuticals media release, the registrational Phase 3 study in obese and overweight patients in China has been initiated in November 2024.